Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with
intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing …

The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Background Cytidine deamination that is guided by clustered regularly interspaced short
palindromic repeats (CRISPR) can mediate a highly precise conversion of one nucleotide …

We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy |
Nature Medicine Skip to main content Thank you for visiting nature.com. You are using a browser …

Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in cancer
care since the approval of tisagenlecleucel by the Food and Drug Administration in 2017 for …

Enhancing CRISPR-mediated site-specific transgene insertion efficiency by homology-
directed repair (HDR) using high concentrations of double-stranded DNA (dsDNA) with …

Genome editing of allogeneic T cells can provide “off-the-shelf” alternatives to autologous
chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain …

Natural killer (NK) cells are unique immune effectors able to kill cancer cells by direct
recognition of surface ligands, without prior sensitization. Allogeneic NK transfer is a highly …